Use and Sequencing of Novel Treatments in NMIBC

Experts discuss where they are using FDA-approved treatments for bacille Calmette-Guérin (BCG)–unresponsive patients in their practice, how they choose between these treatments, and how these advances have impacted the timing of radical cystectomy for patients.

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 4.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 5.TAR-200 Clinical Development Program in NMIBC

EP: 6.Other Investigational Drug Delivery Systems in NMIBC

EP: 7.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 8.FDA-Approved Treatments for BCG-Unresponsive NMIBC

Now Viewing

EP: 9.Use and Sequencing of Novel Treatments in NMIBC

EP: 10.Communication of Treatment Options for High-Risk NMIBC

EP: 11.Checkpoint Inhibitors for Treatment of NMIBC

EP: 12.Unmet Needs in NMIBC

EP: 13.Operationalizing TAR-200 and Other Delivery Systems in Practice

EP: 14.Patient Communication and Treatment Adherence in NMIBC

EP: 15.Uptake of New Treatments in Urology Practice

EP: 16.Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

• Where are you using these treatments in your practice, and how do you choose between them for BCG-unresponsive patients?
• How have these advances changed the timing of radical cystectomy for patients?

Related Videos